3G0 Stock Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Altimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.50 |
| 52 Week High | US$13.70 |
| 52 Week Low | US$1.97 |
| Beta | 0.059 |
| 1 Month Change | -19.62% |
| 3 Month Change | -26.51% |
| 1 Year Change | 26.63% |
| 3 Year Change | -38.55% |
| 5 Year Change | 176.99% |
| Change since IPO | -96.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3G0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.4% | -4.9% | -1.5% |
| 1Y | 26.6% | -19.9% | 0.9% |
Return vs Industry: 3G0 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 3G0 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 3G0 volatility | |
|---|---|
| 3G0 Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3G0's share price has been volatile over the past 3 months.
Volatility Over Time: 3G0's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
| 3G0 fundamental statistics | |
|---|---|
| Market cap | €468.91m |
| Earnings (TTM) | -€83.10m |
| Revenue (TTM) | €400.23k |
1,172x
P/S Ratio-5.6x
P/E RatioIs 3G0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3G0 income statement (TTM) | |
|---|---|
| Revenue | US$426.00k |
| Cost of Revenue | US$65.80m |
| Gross Profit | -US$65.37m |
| Other Expenses | US$23.07m |
| Earnings | -US$88.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | -15,345.77% |
| Net Profit Margin | -20,762.21% |
| Debt/Equity Ratio | 0% |
How did 3G0 perform over the long term?
See historical performance and comparison